July 23, 2014 3:30 PM ET

Pharmaceuticals

Company Overview of TheraVida, Inc.

Company Overview

TheraVida, Inc., a clinical-stage biopharmaceutical company, develops and commercializes pharmaceutical products in the fields of urology and central nervous system disorders. The company focuses on programs for the improved treatment of overactive bladder (OAB) and urge urinary incontinence. Its product Tolenix (THVD-201) is a combination of tolterodine, a muscarinic antagonist used to treat OAB; and pilocarpine, a muscarinic agonist to treat dry mouth (xerostomia). The company’s Tolenix drug platform is applied to anti-muscarinic therapies, such as ditropan (oxybutynin) or detrol (tolterodine) to eliminate the dry mouth side effect associated with these agents. TheraVida, Inc. was founded ...

177 Bovet Road

Suite 600

San Mateo, CA 94402

United States

Founded in 2005

Phone:

650-638-2335

Fax:

650-341-1395

Key Executives for TheraVida, Inc.

Chairman and Chief Executive Officer
Founder
Age: 59
Vice President of Pre-Clinical & Clinical Development
Clinical & Scientific Advisor
Clinical & Scientific Advisor
Compensation as of Fiscal Year 2014.

TheraVida, Inc. Key Developments

TheraVida, Inc. and SK Chemicals Announce License Agreement for the Development and Commercialization of THVD-201 and THVD-202 for Overactive Bladder in South Korea

TheraVida, Inc. and SK Chemicals Co. Ltd. announced the execution of a license agreement for two of TheraVida's proprietary combination drug product candidates, THVD-201 and THVD-202. The agreement grants SK Chemicals exclusive rights to develop and commercialize THVD-201 and THVD-202 in South Korea for the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI). THVD-201 is a proprietary twice-daily (BID) formulation of tolterodine and pilocarpine that is designed to treat OAB and UUI with reduced dry mouth side effects frequently associated with currently available treatments. THVD-201 has completed Phase 1 and Phase 2 development in international clinical trials. THVD-202 is a proprietary once-daily (QD) formulation of tolterodine and pilocarpine that is completing pre-clinical development. According to the agreement, SK Chemicals is responsible for costs associated with the manufacturing, Phase 3 clinical development, regulatory approval, and commercialization of THVD-201 in South Korea. SK Chemicals is also responsible for clinical development, approval, and commercialization of follow-on product THVD-202 in the territory. In return for the exclusive license to THVD-201 and THVD-202 in South Korea, TheraVida shall receive milestone payments and a royalty on net sales of the products by SK Chemicals.

TheraVida, Inc. Announces Phase II Results for Tolenix in Patients with Overactive Bladder and Urge Urinary Incontinence

TheraVida, Inc. announced positive results from a Phase 2 clinical trial of its lead product candidate Tolenix for the treatment of overactive bladder and urge urinary incontinence. Tolenix is a twice-daily proprietary combination of tolterodine, a muscarinic antagonist used to treat OAB, and pilocarpine, a muscarinic agonist approved to treat dry mouth. The objectives of the randomized, double-blinded, multiple-crossover Phase 2 trial were to assess the safety and efficacy of Tolenix in reducing the frequency of micturition and incontinence episodes per day, as compared to both placebo control and active control Detrol. In addition, common side effects of muscarinic antagonist therapies, such as dry mouth, were carefully assessed in the 138 patients enrolled in the trial. This international Phase 2 clinical trial was conducted in South Korea, Australia, and New Zealand. Patients receiving Tolenix experienced statistically significant improvements in their OAB and UUI symptoms over placebo control, as well as efficacy similar in magnitude to the maximum dose of active control Detrol. Patients receiving Tolenix exhibited no significant safety issues, and demonstrated statistically significant and clinically meaningful improvements in their saliva production and dry mouth side effects, as compared to active control Detrol . This Phase 2 study also demonstrated a favorable therapeutic index, which may enable higher dosing of Tolenix in some patients. A higher dose of Tolenix was studied in a 12-week open-label extension period, in a subset of patients in this Phase 2 trial. In this extension period, the higher dose of Tolenix exhibited the potential to provide greater bladder control, while minimizing dry mouth side effects. TheraVida intends to conduct additional international clinical trials of Tolenix in patients with OAB and UUI.

TheraVida, Inc. Presents at EBD Group AG's Biotech showcase 2013, Jan-08-2013 03:45 PM

TheraVida, Inc. Presents at EBD Group AG's Biotech showcase 2013, Jan-08-2013 03:45 PM. Venue: Parc 55 Wyndham Union Square Hotel, San Francisco, California, United States.

Similar Private Companies By Industry

Company Name Region
Odyssey Pharmaceuticals, Inc. United States
Trigemina, Inc. United States
Bryce Rx Laboratories, Inc. United States
BML Pharmaceuticals, Inc. United States
SSL Americas, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TheraVida, Inc., please visit www.theravida.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.